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ORIGINAL ARTICLE
Squamous cell carcinoma (SCC) of the ovary can
arise from an ovarian mature cystic teratoma,1
ovarian endometriosis,2,3 a Brenner tumor, or
solely from an ovarian surface epithelium.4,5 Of
these, SCC arising from a mature cystic teratoma
is the one most frequently encountered; however,
such carcinomas are rare and have been reported
only sporadically.6 On the other hand, mature
cystic teratomas are the most common germ cell
tumor of the ovary, accounting for as many as
10% of all ovarian neoplasms.6 Of the instances
of malignant change reported for mature cystic
teratomas, SCCs make up over 80% of all cases.7
Other rare malignancies that may originate from
Prognosis and Treatment of Squamous Cell
Carcinoma from a Mature Cystic Teratoma 
of the Ovary
Ruey-Jien Chen,1* Ko-Yang Chen,2 Ting-Chen Chang,1 Bor-Ching Sheu,1
Song-Nan Chow,1 Su-Cheng Huang1
Background/Purpose: Squamous cell carcinoma (SCC) arising from a mature cystic teratoma of the ovary
is rare and only reported sporadically. Clinical information on the disease is limited. This study assesses
the clinical characteristics, treatment, outcome and prognostic factors of reported cases.
Methods: Two hundred and twenty cases from 1976 through to 2005 in MEDLINE were analyzed for patient
age, clinical and laboratory data, extent of disease, tumor markers, treatment and survival rates. Only the
188 cases with surgical staging were included in the survival analysis.
Results: The disease occurred most often in elderly women (mean, 55.0 ± 14.4 years) and cysts were large
(mean, 13.7 ± 5.7 cm). Abdominal pain (71.6%) was the most common symptom. Preoperative serum
SCC antigen level had a high positive rate (81.3%). Overall 5-year survival rate for all stages was 48.4%. For
Stage I, the 5-year survival rate was 75.7%; stage II, 33.8%; stage III, 20.6%; and stage IV, 0% (p < 0.0001).
Univariate analysis revealed that tumor stage, patient age, tumor size, preoperative SCC antigen and CA125
levels, and optimal debulking were significant prognostic factors. Further investigation into treatments for
all stages revealed that postoperative adjuvant chemotherapy may produce a better survival rate for both
stage III and stage IV cases. However, postoperative radiotherapy did not show a similar effect. Multivariate
analysis indicated that stage and optimal debulking were significant factors that influenced survival.
Conclusion: A mature cystic teratoma should be treated as early as possible. Tumor stage and optimal 
debulking are critical to survival. Unlike SCCs of the uterine cervix, postoperative adjuvant chemotherapy
may produce a better result than adjuvant radiotherapy for advanced-stage cases. [J Formos Med Assoc
2008;107(11):857–868]
Key Words: cancer staging, cystic teratoma, ovarian neoplasm, squamous cell carcinoma
©2008 Elsevier & Formosan Medical Association
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1Department of Obstetrics and Gynecology, National Taiwan University Hospital and National Taiwan University
College of Medicine, and 2Graduate Institute of Biomedical Electronics and Bioinformatics, College of Electrical
Engineering and Computer Science, National Taiwan University, Taipei, Taiwan.
Received: February 12, 2008
Revised: April 8, 2008
Accepted: May 21, 2008
*Correspondence to: Dr Ruey-Jien Chen, Department of Obstetrics and Gynecology,
National Taiwan University Hospital, 7 Chung-Shan South Road, Taipei 100, Taiwan.
E-mail: rjchen@ntu.edu.tw
mature cystic teratomas include adenocarcinoma,
carcinoma, malignant melanoma, transitional cell
carcinoma, thyroid adenocarcinoma and sarco-
matous changes.8 Because of its rarity, the current
literature on the disease exhibits a paucity of sta-
tistical analysis based on a data set that is often
limited to the medical facility where the study
was conducted. Its clinical characteristics, treat-
ment and prognosis are thus poorly understood.
Moreover, some case reports revealed that SCCs
arising from a mature cystic teratoma have a poor
prognosis despite aggressive treatment.9,10 There
is also a lack of consensus in the literature regard-
ing adjuvant treatment. A systematic analysis based
on the cases reported in the literature may thus
produce a better understanding of the disease.
Methods
Patients
Using MEDLINE, we reviewed the literature from
1976 through to 2005 to identify cases of SCC
arising from a mature cystic teratoma of the ovary.
In searching for these articles, we used the terms
“squamous cell carcinoma”, “ovarian cancer”,
“ovarian neoplasms”, “dermoid cyst” and “benign
cystic teratoma”, first individually and then in
combination. Only cases reported in English were
included. A total of 220 cases from 44 articles
were found. Each article was reviewed carefully
to obtain as much relevant data as possible. The
following data were obtained: patient age, symp-
toms and signs, tumor size, laterality, preopera-
tive tumor marker levels (including SCC antigen,
CA125, CA199 and carcinoembryonic antigen
[CEA]), tumor stage, tumor grade, treatment, sur-
gical findings, tumor extent, patient outcome
and survival data. For patients who underwent
surgery, tumor stage was determined by surgical
staging; here, we followed the International
Federation of Gynecology and Obstetrics (FIGO)
staging system. Cases with carcinoma in situ were
also included in this study. Treatments were
grouped according to type of surgery, radiother-
apy or chemotherapy. Surgical methods included
oophorocystectomy/oophorectomy, hysterectomy
plus oophorectomy, hysterectomy, oophorectomy
plus another abdominal surgery such as omentec-
tomy, urinary bladder cystectomy, intestinal re-
section, or resection of other abdominal organs,
and lymph node dissection. Where biopsy was
the only surgical procedure, the surgical method
was categorized as exploratory laparotomy. This
study was approved by the Institutional Review
Board of the National Taiwan University Hospital.
Statistical analysis
Statistical calculations and analyses were per-
formed. Student’s t test was used to determine the
significance of differences between continuous
data. The Kruskal-Wallis test was used for non-
parametric data. Categorical variables were tested
using the χ2 test, the Kruskal-Wallis test or one-way
ANOVA. Estimated survival probabilities were
plotted using the Kaplan-Meier method. Survival
differences between groups were analyzed by the
log-rank test. The Cox proportional hazards model
was also used for simultaneously assessing the sig-
nificance of multiple variables to identify factors
associated with survival. Results were considered
statistically significant if the p value was < 0.05.
Results
The clinical and pathologic characteristics of the
220 cases are shown in Table 1.1,7–49 However,
because of the disease’s rarity, and because the
objectives of the case reports varied, a complete
set of data was unavailable for analysis. Instead,
although many reports provided relevant clinical
and pathology findings, only some included pre-
operative laboratory data concerning tumor mark-
er levels (Table 1). Survival data were analyzed for
the 188 cases with surgical staging (Table 2).
Based on our analysis, SCC arising from a ma-
ture cystic teratoma occurs most commonly in
elderly patients. For all 220 cases, mean patient
age was 55.0 ± 14.4 years. As for age distribution,
the youngest patient was 21 years old and the old-
est was 87; furthermore, 66.8% were at least 50.
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However, the age distribution was not found to
be statistically significant for the various tumor
stages (p > 0.05).
Most cases were discovered at stage I (44.5%)
and stage III (30.9%). For the 98 stage I cases, 76
(77.6%) were stage Ia, 18 (18.4%) were stage Ic,
and four (4.1%) were an unspecified stage I sub-
stage. For the 33 stage II cases, four (12.1%) were
stage IIa, 15 (45.5%) were stage IIb, and 14
(42.4%) were stage IIc. For the 68 stage III cases,
four (5.9%) were stage IIIa, five (7.4%) were stage
IIIb, 20 (29.4%) were stage IIIc, and 39 (57.4%)
were an unspecified stage III substage.
The mean cyst size was 13.8 ± 5.7 cm (range,
4.0–35 cm) in the 150 cases where cyst size was
reported. The mean cyst sizes were as follows: for
carcinoma in situ, 10.9 ± 5.54 cm (n = 4); for stage
I, 13.1 ± 5.1 cm (n = 73); for stage II, 14.6 ± 6.3 cm
(n = 26); for stage III, 14.7 ± 6.3 cm (n = 37); for
stage IV, 12.5 ± 4.4 cm (n = 7); and for cases with
an unspecified stage, 16.3 ± 5.7 cm (n = 3). Mean
cyst size did not vary significantly between the
various tumor stages (p > 0.05).
Of the 132 cases where cyst laterality was
known, most occurred on one ovary (96.2%).
Only 3.8% were bilateral. For unilateral tumors,
55.1% occurred on the right side of the ovary
and 44.9% were found on the left side. Using the
χ2 test, bilaterality did not seem to be linked to
the advanced stages of this cancer (p = 0.072).
Clinical symptoms were reported in 74 cases.
Abdominal pain was the most frequent symp-
tom (71.6%). The next most frequent clinical
presentation was abdominal swelling or abdom-
inal mass (58.1%). Other symptoms included
menorrhagia, urinary retention, diarrhea, fever,
and cachexia.
The positive rate for SCC antigen was high
(81.3%). The positive rates for other markers
were 65.0% for CEA, 64.7% for CA199, and
59.1% for CA125. The positive rates for the four
tumor marker levels did not significantly corre-
late with either tumor stage (p > 0.05) or tumor
size (p > 0.05).
Initial treatment methods were reported in 191
cases. Of these, 188 underwent surgery. The other
Table 1. Characteristics of squamous cell
carcinoma arising from a mature cystic
teratoma of the ovary
Characteristics n (%)
Age (yr) 220
Mean ± SD 55.0 ± 14.4
Range 21–87
< 40 33 (15.0)
40–49 40 (18.2)
50–59 58 (26.3)
60–69 55 (25.0)
> 69 34 (15.5)
Stage 220
Carcinoma in situ 6 (2.7)
Stage I 98 (44.5)
Stage II 33 (15.0)
Stage III 68 (30.9)
Stage IV 7 (3.2)
Unstaged 8 (3.6)
Size (cm)* 150
Mean ± SD 13.8 ± 5.7
Range 4.0–35.0
< 10 32 (21.3)
≥ 10 118 (78.7)
Laterality* 132
Left 57 (43.2)
Right 70 (53.0)
Bilateral 5 (3.8)
Symptoms and signs*† 74
Abdominal pain 53 (71.6)
Abdominal swelling or mass 43 (58.1)
Other 14 (18.9)
Tumor grade* 111
Grade 1 30 (27.0)
Grade 2 52 (46.8)
Grade 3 29 (26.1)
SCC antigen* 32
Positive 26 (81.3)
Mean ± SE (ng/mL) 17.3 ± 4.4
CA125* 44
Positive 26 (59.1)
Mean ± SE (U/mL) 106.3 ± 20.9
CA199* 34
Positive 22 (64.7)
Mean ± SE (U/m) 2161.6 ± 872.1
CEA* 20
Positive 13 (65.0)
Mean ± SE (ng/mL) 15.2 ± 4.1
*Only some of the reports provided this information; †one case
may have more than one symptom. SD = standard deviation; SCC =
squamous cell carcinoma; SE = standard error; CEA = carcinoembry-
onic antigen.
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Table 2. Univariate analysis of survival rates for squamous cell carcinoma arising from a mature cystic teratoma of the ovary
Total (n) Median survival (mo) 2-yr survival rate (%) 5-yr survival rate (%) p*
All cases 188 41.8 53.0 48.4
Age 188 0.0310
Below mean age (≤ 55.0 yr) 95 NR 59.6 58.1
Above mean age (> 55.0 yr) 93 21 47.9 39.8
Stage† 188 < 0.0001
Carcinoma in situ 5 NR 100 100
I 89 NR 75.7 75.7
II 30 15 40.6 33.8
III 61 8 32.3 20.6
IV 3 4.5 15.0 NR
Cyst size above mean (> 13.8 cm)† 136 0.0349
No 73 NR 53.5 50.5
Yes 63 15 42.2 42.2
Laterality† 110 0.6386
Left 49 41.8 52.1 44.7
Right 56 60 52.5 46.8
Bilateral 5 8 40.0 NR
Symptoms†‡ 69 0.1769
Abdominal pain 49 14 33.1 33.1
Abdominal fullness or mass 42 18 43.1 34.0
Other symptoms 14 9.5 17.0 NR
Tumor grade† 108 0.3281
1 30 NR 71.4 71.4
2 49 NR 58.8 54.9
3 29 33 53.2 49.1
SCC antigen† 32 0.0415
Negative 6 NR 83.3 83.3
Positive 26 15 48.9 39.1
CA125† 42 0.0004
Negative 16 NR 92.9 92.9
Positive 26 12 32.0 18.0
CA199† 32 0.8297
Negative 10 NR 55.6 55.6
Positive 22 NR 64.8 54.0
CEA† 20 0.3731
Negative 7 NR 66.7 66.7
Positive 13 41.8 57.5 43.2
SCC antigen and CA125† 31 0.0114
All negative 4 NR 100 100
One positive, one negative 10 NR 78.8 78.8
Both positive 17 11 27.9 13.9
(Contd.)
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three cases were managed without surgery: one
with radiotherapy plus chemotherapy, and two
with supportive treatment only.
Of the 188 cases that were initially managed
with surgery, 185 were laparotomies while only
three were laparoscopies. When a laparotomy was
performed, initial surgical methods included: oo-
phorocystectomy/oophorectomy (n = 48, 25.9%);
hysterectomy plus oophorectomy (n = 62, 33.5%);
hysterectomy plus oophorectomy plus another
abdominal surgery (n = 69, 37.3%) such as omen-
tectomy, urinary bladder cystectomy, intestinal
resection, resection of other abdominal organs, or
lymph node dissection; and exploratory laparo-
tomy only (n = 6, 3.2%). Among the 188 cases
that were treated surgically, 37.2% (70/188) un-
derwent surgery alone, while 16.5% (31/188)
underwent postoperative adjuvant radiotherapy,
31.4% (59/188) had postoperative chemother-
apy, and 14.9% (28/188) underwent both post-
operative radiotherapy and chemotherapy. A
higher percentage of patients with an advanced-
stage case (73/94, 77.7%) underwent chemother-
apy and/or radiotherapy than those with an
early-stage case (45/94, 47.9%; p < 0.0001, Fisher’s
exact test). Of the 28 patients who underwent
both treatments, the temporal sequence of post-
operative radiotherapy in relation to chemother-
apy was given: four had chemotherapy first, seven
underwent radiotherapy first, and 12 had concur-
rent therapy. Survival rates between these groups
did not differ statistically (p > 0.05).
In the 98 cases where we could determine that
the surgery was optimal, we found that the per-
centage of cases with optimal debulking surgery
decreased as the tumor stage increased. The opti-
mal debulking rate for carcinoma in situ was 100%
(2/2); for stage I was 97.9% (47/48); for stage II
was 50.0% (8/16); for stage III was 20.7% (6/29);
for stage IV was 0% (0/2); and for unstaged cases
was 0% (0/1) (p < 0.0001).
Of the 98 stage I cases of the disease, a laparo-
tomy was performed in 95 patients while three
were initially treated by laparoscopic removal.
The tumors from these three patients were uni-
lateral. The laparoscopic removal of the cyst was
performed under a preoperative clinical impres-
sion of mature cystic teratoma.31,45,46 Patient age
ranged from 28 to 37 years. Teratoma size was
5–7 cm and the cyst was located at the right ovary
in all three cases. During laparoscopy, all findings
were consistent with a dermoid cyst. However,
spillage of tumor contents occurred; in one case,
the cyst was found to have spontaneously rup-
tured during laparoscopy, and in the other two
cases spillage occurred when the cyst was being
removed. Despite the fact that the dermoid cyst’s
contents were removed by suction and irrigation
was used to remove spillage, a later staging laparot-
omy revealed in all three cases that spillage of
the cyst’s contents during laparoscopic removal
resulted in an upstaging from FIGO stage Ic to
IIc–IIIc. These staging laparotomies were per-
formed because of pathology reports that revealed
Table 2. Continued
Total (n) Median survival (mo) 2-yr survival rate (%) 5-yr survival rate (%) p*
Mode of treatment† 188 0.1267
Surgery alone 70 NR 65.3 65.3
Surgery with RT 31 15 42.5 42.5
Surgery with CT 59 NR 55.0 52.6
Surgery with RT and CT 28 21 22.3 22.3
Optimal debulking† 98 < 0.0001
Yes 63 NR 79.1 76.0
No 35 24 49.9 24.5
*Comparison of survival curves by log-rank test; †only some of the reports provided this information; ‡one case may have more than one symptom. RT =
radiotherapy; CT = chemotherapy; NR = not reached.
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a dermoid cyst with a SCC: 1 week after the ini-
tial laparoscopic removal in one case,46 33 days
later in another,31 and 2 months later in the last
case (due to the spreading of the tumor).45 Peri-
toneal, omental and retroperitoneal implants of
the tumor were found. Retroperitoneal lymph
nodes were also discovered. Extensive surgeries
were performed, and all three patients underwent
postoperative adjuvant cisplatin-based multiagent
chemotherapy, with one patient undergoing con-
current radiotherapy. Two of these patients died
of the disease 16 and 19 months after laparoscopic
surgery, while one was disease-free for 4 years.
During our research, we found no report in the
literature of a case of a mature cystic teratoma
that was later found to have a SCC that was suc-
cessfully treated by laparoscopic removal without
complications.
Out of 220 cases, survival data were analyzed
for the 188 (85.4%) patients with surgical stag-
ing. For carcinoma in situ, no patient died of the
disease. For stage I, 20 of the 89 patients died.
Eighteen of these 20 patients (90%) died within
2 years of initial treatment. For later stages (stages
II to IV), 62 of 94 patients died. Of the 32 sur-
vivors (13 stage II, 19 stage III), 23 survived for at
least 2 years (8 stage II, 15 stage III). For stage III,
nine survived for over 4 years. Of the 23 stage II
and III patients who survived for at least 2 years,
13 (56.5%) had undergone surgery plus adju-
vant chemotherapy, three (13.0%) had surgery
plus adjuvant radiotherapy, and seven (30.4%)
had surgery plus both chemotherapy and radio-
therapy. The median survival period was 41.8
months. The overall 5-year survival rate was 48.4%
(Figure 1). The 5-year survival rate was 100% for
carcinoma in situ, 75.7% for stage I, 33.8% for
stage II, 20.6% for stage III and 0% for stage IV.
Elderly patients had a worse prognosis than
younger patients (p < 0.05, Table 2). In most
cases, the cause of death was tumor-related; in
only one case was death attributable to old age.
That is, among the 82 patients who were reported
as deceased, the cause of death was tumor-related
in 78 cases (due to the persistence or recurrence
of the tumor) and was not tumor-related in four
cases. For cases where the cause of death was not
tumor-related, one patient died of acute myelog-
enous leukemia, two died of surgical complications,
and one died of old age.
Patients with a larger tumor (greater than a
mean size of 13.8 cm) also had a worse progno-
sis than patients with a smaller tumor (p < 0.05).
The type of major symptom, tumor laterality, and
tumor grade had no significant effect on survival
rates (all p > 0.05).
Preoperative tumor markers were also evalu-
ated to determine their relationship with prog-
nosis. Cases with a negative preoperative CA125
level (n = 16) had a better prognosis than those
with a positive preoperative CA125 level (n = 26,
p=0.0004). Cases with a negative test result for pre-
operative SCC antigen (n = 6) had a better prog-
nosis than those with a positive test result for it
(n=26, p=0.0415). When we consider SCC antigen
and CA125 together, cases where positive levels of
both were present had a worse 5-year survival rate
(13.9%). When only one of the two markers was
positive, the survival rate was 78.8%; when both
were negative, we found a 100% 5-year survival rate
(p = 0.0114). Although the preoperative detection
of SCC antigen or CA125 levels seems to be a use-
ful way of predicting the severity of the disease,
preoperative CA199 (p > 0.05) and CEA (p > 0.05)
levels did not correlate with a patient’s survival.
For the 188 cases where treatment methods
and survival status could be analyzed, we found
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Figure 1. Survival curves with 95% confidence intervals
for squamous cell carcinoma arising from a mature cystic
teratoma of the ovary.
that survival rates did not differ significantly 
between cases with surgery alone, with adjuvant
radiotherapy, with adjuvant chemotherapy, or with
both (p > 0.05). However, for patients who un-
derwent surgery, survival rates for those who un-
derwent optimal debulking surgery were better
(p < 0.0001, Table 2).
We also analyzed the effect of treatment
methods on survival for every stage. For the 76
stage Ia cases with survival data, the results
showed that the survival rate for oophorocystec-
tomy/oophorectomy did not differ statistically
from other surgeries; oophorectomy plus hys-
terectomy, or oophorectomy plus omentectomy,
and retroperitoneal lymphadenectomy (p > 0.05).
For stage Ia, the survival curves did not differ sta-
tistically for cases with or without postoperative
chemotherapy (p > 0.05). Nor did the survival
curves differ statistically between cases with or
without postoperative radiotherapy (p > 0.05). For
the stage Ic cases, Kaplan-Meier analysis revealed
that survival rates did not differ between surgery
alone and surgery with adjuvant radiotherapy or
chemotherapy or both (p > 0.05). For stage II, we
found that differences in survival rates did not
reach significance between cases with surgery
alone and those with surgery plus postoperative
adjuvant therapies (p > 0.05); neither postopera-
tive adjuvant chemotherapy nor radiotherapy
nor both improved survival rates. For stage III
cases, survival rates differed significantly between
surgery alone and surgery with adjuvant radio-
therapy or chemotherapy or both (p = 0.0342,
Figure 2). We found that for stage III cases, a sig-
nificant difference in survival rates occurred 
between adjuvant chemotherapy (mostly cisplatin-
based multiagent) and surgery alone (hazard
ratio, 2.706; 95% CI, 2.018–12.71; p = 0.0005),
but not between adjuvant radiotherapy and sur-
gery alone (hazard ratio, 1.144; 95% CI, 0.6068–
2.211; p > 0.05). For stage IV cases, differences in
survival rates between surgery alone and surgery
with adjuvant radiotherapy or chemotherapy or
both are shown in Figure 3 (p=0.0575). A signifi-
cant difference in survival rates was found between
adjuvant chemotherapy (mostly cisplatin-based
multiagent) and surgery alone (hazard ratio,
5.036; 95% CI, 1.868–232.2; p = 0.0136), but not
between adjuvant radiotherapy and surgery alone
(hazard ratio, 0.8266; 95% CI, 0.06863–9.162;
p > 0.05). The mean age of patients with postop-
erative chemotherapy was 53.9 ± 14.0 years, while
the mean age of those without postoperative
chemotherapy was 55.3 ± 15.4 years. Thus, there
was no statistically significant age-based difference
between the two groups (p > 0.05). There does not
seem to have been a preference for chemotherapy
in younger patients.
We also used multivariate analysis by the Cox
proportional hazards model to evaluate the in-
dependent factors that could influence survival
Ovarian squamous cell carcinoma
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Figure 2. Survival curves comparing surgery alone with
surgery plus adjuvant radiotherapy (RT) or adjuvant chemo-
therapy (CT) or both for stage III squamous cell carcinoma
arising from a mature cystic teratoma of the ovary.
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Figure 3. Survival curves comparing surgery alone with
surgery plus adjuvant radiotherapy (RT) or adjuvant che-
motherapy (CT) or both for stage IV squamous cell carci-
noma arising from a mature cystic teratoma of the ovary.
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rates. In the regression model, patient age, tumor
stage, size of mature cystic teratoma, tumor later-
ality, major symptoms, mode of treatment and
optimal debulking were included (Table 3). Mul-
tivariate analysis revealed that only tumor stage
(p = 0.0371) and optimal debulking (p = 0.0112)
were independent factors for survival.
Discussion
SCC arising from a mature cystic teratoma of the
ovary has been reported sporadically and not an-
alyzed systematically. Its treatment, outcome and
prognostic factors are still not well understood.
In this paper, we analyzed 220 cases reported
over a period of 30 years (from 1976 through to
2005). Because of the rarity of the disease, in this
study we included all reports available during
this long period of time despite the fact that
many articles varied in their aims and usually did
not provide all relevant clinical, laboratory, pathol-
ogy and survival data. There is thus a significant
risk of reporting bias inherent in a study such as
ours. However, as far as we know, this report is
the largest systematic analysis of the disease.
In our study, we found that this disease oc-
curs most frequently in elderly women. This age
distribution is comparable with earlier reports on
ovarian epithelial cancers like mucinous or serous
adenocarcinoma.50–53 On the other hand, mature
cystic teratomas were reported as occurring most
frequently in younger women during their repro-
ductive years (mean age of 35.4 years).54
We also found that the mean size of a mature
cystic teratoma with a SCC was quite large:
13.8 cm. Of these cysts, 78.7% were larger than
10 cm. In contrast, the mean size of mature cystic
teratomas without malignancy seems to be
smaller, with a reported mean size of around
4–6 cm.55–57 Thus, the mean size of teratomas
that harbor SCC tissue is larger than those that
lack malignant tissue. These results suggest that
when a large mature cystic teratoma is discov-
ered, a malignant transformation that produces 
a SCC may have occurred. Such a mature cystic
teratoma should be treated as early as possible.
Ovarian dermoid cysts have been reported as
having a right-lateral predisposition.55 As for other
ovarian malignancies, laterality has also been
found to be associated with histologic type.58
Serous tumors of the ovary are more commonly
bilateral (57.5%) than ovarian tumors of other
histologic subtypes, such as mucinous (21.3%),
clear cell (13.3%), and endometrioid (26.8%).
Among women with a unilateral tumor, the right
and left ovaries were affected with about equal
frequency.58 In our analysis, we found that SCCs
arising from a mature cystic teratoma were mostly
unilateral (96.2%), with 55.1% being located 
at the right ovary and 44.9% at the left ovary.
However, this tendency for SCCs to be located at
the right ovary did not reach the level of statistical
significance.
We believe our analysis shows that testing for
serum SCC antigen positivity is a useful tool for
the preoperative detection of SCCs that have
arisen from a mature cystic teratoma of the ovary.
Table 3. Multivariate analysis of survival rates for squamous cell carcinoma arising from a mature cystic teratoma of the ovary
95% CI
B SE Exp(B)
Lower Upper
p
Age −6.9178 3.8029 9.90E-04 7.73E-07 1.7087 0.0689
Tumor stage −2.0436 0.9801 0.1296 0.0190 0.8845 0.0371
Size 2.2100 1.5270 9.1157 0.4571 181.7799 0.1478
Tumor laterality 2.0745 1.8704 7.9626 0.2037 311.3017 0.2673
Major symptoms −2.1492 1.5924 0.1166 0.0051 2.6426 0.1771
Mode of treatment 1.6208 1.0202 5.0569 0.6846 37.3523 0.1122
Optimal debulking −19.0869 7.5296 5.137E-09 2.002E-15 0.0132 0.0112
Among four tumor markers, SCC antigen, CA125,
CA199, and CEA, we found that SCC antigen
had the highest positive rate (81.3%). A lower
positive rate (15%) for SCC antigen was found
in nonmalignant mature cystic teratomas.59 More-
over, because preoperative positive levels of both
the SCC antigen and CA125 were associated with
survival rates, we feel that it is necessary to per-
form preoperative tests for the two markers. How-
ever, because approximately 60% of reported
cases had a preoperative positive test result for
CA125, and because more than 80% had a posi-
tive test result for the SCC antigen, we can also
see that the percentage of positive test results for
CA125 corresponds more closely to the 50% 
5-year survival rate than does the positive rate 
for the SCC antigen. A positive CA125 level thus
seems to be a more reliable means of predicting
whether or not a case of SCC will have a poor
prognosis.
For stage Ia, we found that the survival rate for
patients who underwent oophorocystectomy/
oophorectomy did not differ statistically from
the rates for more advanced surgeries. Moreover,
survival curves did not differ statistically between
cases with or without postoperative chemother-
apy, nor did survival curves differ statistically 
between cases with or without postoperative ra-
diotherapy. These results suggest that stage Ia SCCs
that arise from a mature cystic teratoma can be
treated by conservative surgery, either oophoro-
cystectomy or oophorectomy.
In recent years, laparoscopic surgery has been
used increasingly for the treatment of benign ovar-
ian cysts such as mature cystic teratomas. This has
occurred despite the fact that spillage of the cyst’s
contents during laparoscopy may lead to the rapid
spread of the disease within the peritoneal cavity.
For the three reported cases initially treated by
laparoscopic removal, a staging laparotomy with
aggressive adjuvant therapy was performed. Two
of these cases ended in the patient’s death. We
have not found any report in the literature where
a case of mature cystic teratoma that was later
found to harbor a SCC was successfully treated
by laparoscopic removal without complications.
However, because of the rarity of reported cases,
it remains uncertain whether progressing from
stage Ia to stage II or III affects the prognosis.
Because spillage may lead to the subsequent up-
staging of the cancer, and thus may lead to a sig-
nificant increase in patient morbidity, we should
keep in mind the possibility of a malignant
transformation of a mature cystic teratoma when
using laparoscopy to treat an ovarian mass.
The univariate analyses we performed re-
vealed that tumor stage, patient age, cyst size, a
positive preoperative test result for CA125 or
SCC antigens, and optimal debulking were fac-
tors that influenced survival. Mode of treatment
was not found to be a significant factor. How-
ever, for stage III cases, patients who had surgery
with chemotherapy (but not surgery with radio-
therapy) were found to have a better prognosis
than those who underwent surgery alone. For 
advanced-stage cases, postoperative adjuvant
chemotherapy may thus produce a better result
than postoperative adjuvant radiotherapy. Using
the Cox proportional hazards model, we discov-
ered that tumor stage and optimal debulking
were the factors that most significantly influ-
enced survival. In ovarian epithelial cancer, age,
performance status, disease stage, and extent of
cytoreductive surgery are important independent
prognostic factors for survival.60,61 These results
for ovarian epithelial cancer underline the impor-
tance of improved surgical management of ovar-
ian cancer, as optimal debulking is the only
prognostic factor achievable;61 they are also com-
patible with our findings for SCC arising from
mature cystic teratoma of the ovary. The reason
that both our univariate and multivariate analy-
ses did not show the mode of treatment to be a
significant survival factor may be due to the fact
that cases at a more advanced stage or with an in-
complete resection would have had chemotherapy
and/or radiotherapy after surgery.
Mature cystic teratomas have the potential 
to undergo malignant transformation to a SCC,
especially in elderly patients who have a big cyst.
A preoperative test for serum SCC may be used
to diagnose this transformation. Conservative 
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surgery may be used to treat stage Ia cases.
Although the proper therapy for stage II–IV tu-
mors remains in doubt, our study suggests that
instead of using radiotherapy, advanced stage
cases may be better treated by optimal debulking
in combination with cisplatin-based chemother-
apy. In contrast to the typically positive response
to radiotherapy shown by SCC of the uterine
cervix,62 radiotherapy does not appear to be very
effective for cases of SCC arising from cystic
tumor of the ovary. This finding may be due to
the fact that ovarian cancer with this type of his-
tology has the same metastatic route as adenocar-
cinomas of the ovary. Finally, because spillage
rates of dermoid cyst contents are inevitably
higher for laparoscopic removal than for excision
using laparotomy for stage I of the disease—even
in young patients, such spillage may upstage the
disease from Ic to stage IIc–III in a later laparo-
tomy—we should be careful when we decide to
remove the teratoma by laparoscopy, especially
when the patient is elderly or the tumor is large.
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